Quince Therapeutics, Inc. (QNCX)
(Delayed Data from NSDQ)
$0.76 USD
-0.03 (-3.77%)
Updated Jun 10, 2024 04:00 PM ET
After-Market: $0.79 +0.03 (3.92%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
QNCX 0.76 -0.03(-3.77%)
Will QNCX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for QNCX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for QNCX
The Zacks Analyst Blog Highlights Quince Therapeutics and XBiotech
Don't Know Much Biology? Tips for Picking Microcap Biotech, Pharma
QNCX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for QNCX
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
Quince Therapeutics announces fast track designation for EryDex System
QNCX Stock Earnings: Quince Therapeutics Reported Results for Q1 2024
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Quince Therapeutics GAAP EPS of -$0.26